公开(公告)号：US20240361339A1

公开(公告)日：2024-10-31

申请号：US18688019

申请日：2022-09-01

申请人： Board of Regents of The University of Nebraska

发明人： Howard GENDELMAN ,  R. Lee MOSLEY ,  Mai MOSTAFA ,  Katherine OLSON ,  Jatinkumar MACHHI

IPC分类号： G01N33/68 ,  A61K38/19

CPC分类号： G01N33/6896 ,  A61K38/193 ,  G01N2333/4703 ,  G01N2333/70596 ,  G01N2333/90216 ,  G01N2333/9027 ,  G01N2333/912 ,  G01N2800/2835 ,  G01N2800/52

摘要： The present disclosure relates to the treatment of Parkinson's disease with granulocyte-macrophage colony-stimulating factor, as well as diagnostic, prognostic and patient selection methods.

公开(公告)号：US20240335545A1

公开(公告)日：2024-10-10

申请号：US18627930

申请日：2024-04-05

申请人： The Medical College of Wisconsin, Inc.

发明人： William R. Clarke ,  Brian F. Volkman ,  Francis C. Peterson ,  Michael B. Dwinell ,  Chad A. Koplinski

IPC分类号： A61K47/55 ,  A61K38/19 ,  A61P37/06

CPC分类号： A61K47/55 ,  A61K38/195 ,  A61P37/06

摘要： Disclosed are methods of treating graft versus host disease (GVHD) or treating ocular graft versus host disease (oGVHD). The methods may comprise administering a therapeutically effective amount of a composition comprising CCL20 locked dimer to a subject, e.g., a subject suffering from GVHD. Also disclosed are modified CCL20LD compositions comprising an unstructured polypeptide.

公开(公告)号：US20240325455A1

公开(公告)日：2024-10-03

申请号：US18734139

申请日：2024-06-05

申请人： University of Maryland, Baltimore

发明人： Sunjay KAUSHAL

IPC分类号： A61K35/34 ,  A61K38/18 ,  A61K38/19 ,  A61P9/10

CPC分类号： A61K35/34 ,  A61K38/1833 ,  A61K38/1866 ,  A61K38/1891 ,  A61K38/19 ,  A61K38/195 ,  A61P9/10

摘要： Embodiments of the disclosure concern compositions and methods of use related to particular c-kit+ mesenchymal cells, including cardiac stem cells, obtained from a pediatric or neonatal individual. In specific embodiments, the cells, or conditioned medium or partial or total secretomes thereof, are provided in an effective amount to an individual in need thereof.

公开(公告)号：US20240317836A1

公开(公告)日：2024-09-26

申请号：US18679187

申请日：2024-05-30

申请人： ImmunityBio, Inc.

发明人： Patrick Soon-Shiong

IPC分类号： C07K14/715 ,  A61K38/17 ,  A61K38/19 ,  A61K38/20 ,  A61K45/06 ,  C07K14/52 ,  C07K14/54 ,  C07K14/71

CPC分类号： C07K14/7155 ,  A61K38/179 ,  A61K38/1793 ,  A61K38/195 ,  A61K38/2086 ,  A61K45/06 ,  C07K14/521 ,  C07K14/5443 ,  C07K14/71 ,  C07K2319/30 ,  C07K2319/31

摘要： Compositions, methods, and uses of recombinant immunoglobulin proteins, recombinant immunoglobulin protein complexes, carrier protein complexes, and a pharmaceutical composition including one or more of those to increase immune therapy effectiveness are presented. Preferred protein and protein complex comprise one or more functional moieties that includes a binding motif to a tumor-associated antigen, a T-cell activating molecule, and a chemokine. In some embodiments, the pharmaceutical composition includes two or more protein complexes, which are functionally distinct from each other. In other embodiments, the pharmaceutical composition includes a genetically-engineered microorganism including a first tumor-associated antigen and a T-cell activating molecule, a recombinant immunoglobulin protein complex, and a chemokine.

公开(公告)号：US20240307534A1

公开(公告)日：2024-09-19

申请号：US18734042

申请日：2024-06-05

申请人： Genentech, Inc.

发明人： Jane L. GROGAN

IPC分类号： A61K39/395 ,  A61K31/7088 ,  A61K38/00 ,  A61K38/19 ,  A61K38/20 ,  A61K38/21 ,  A61K39/00 ,  A61K45/06 ,  A61K47/68 ,  A61P35/00 ,  C07K16/28 ,  C07K16/30 ,  C12N15/113 ,  C12N15/115

CPC分类号： A61K39/39558 ,  A61K31/7088 ,  A61K38/00 ,  A61K38/193 ,  A61K38/20 ,  A61K38/217 ,  A61K39/0011 ,  A61K39/001104 ,  A61K39/001106 ,  A61K39/001109 ,  A61K39/001113 ,  A61K39/001119 ,  A61K39/001124 ,  A61K39/001128 ,  A61K39/001129 ,  A61K39/001138 ,  A61K39/00114 ,  A61K39/001141 ,  A61K39/001166 ,  A61K39/00117 ,  A61K45/06 ,  A61K47/6803 ,  A61K47/6851 ,  A61P35/00 ,  C07K16/2803 ,  C07K16/30 ,  C12N15/1138 ,  C12N15/115 ,  A61K2039/505 ,  A61K2039/5158 ,  A61K2039/545 ,  C07K2317/51 ,  C07K2317/515 ,  C07K2317/56 ,  C07K2317/76 ,  C12N2310/11 ,  C12N2310/12 ,  C12N2310/14 ,  Y02A50/30

摘要： The present disclosure provides methods comprising administering to the individual an effective amount of an agent that decreases or inhibits TIGIT expression and/or activity and an anti-cancer agent and/or an anti-cancer therapy. Further provided are kits comprising an anti-cancer agent, an agent that decreases or inhibits TIGIT expression and/or activity, or both, as well as instructions for use thereof.

公开(公告)号：US20240299514A1

公开(公告)日：2024-09-12

申请号：US18667742

申请日：2024-05-17

申请人： Diamyd Medical AB

发明人： Anders ESSEN-MÖLLER ,  Johnny LUDVIGSSON

IPC分类号： A61K39/00 ,  A61K9/00 ,  A61K31/192 ,  A61K31/197 ,  A61K31/592 ,  A61K31/593 ,  A61K35/12 ,  A61K38/17 ,  A61K38/19 ,  A61K38/28 ,  A61K38/43 ,  A61K45/06

CPC分类号： A61K39/0008 ,  A61K9/0019 ,  A61K31/192 ,  A61K31/197 ,  A61K31/592 ,  A61K31/593 ,  A61K38/1793 ,  A61K38/191 ,  A61K38/28 ,  A61K38/43 ,  A61K45/06 ,  C12Y401/01005 ,  A61K2035/122 ,  A61K2039/54 ,  A61K2039/55505 ,  A61K2039/577

摘要： The present invention relates to a method for prevention and/or treatment of an autoimmune disease, comprising administering a composition, said composition comprising at least one beta cell autoantigen, to a subject The subject may have a serum vitamin-D level above 50 nanomole/liter or the composition may be administered by intralymphatic injection or injection directly into a lymph node, or over a period of weeks, months, or years. The invention also relates to a composition comprising a plurality of particles, each having immobilised on its surface at least one first and at least one second antigen, wherein the first antigen is a beta cell autoantigen, and the second antigen is either a tolerogen or a beta cell autoantigen, and to composition comprising i) at least one beta cell autoantigen, and at least one of iia) an IL-10 inducing compound selected from the group consisting of vitamin-D), vitamin-D analogs, tyrosine kinase inhibitors, gamma-amino butyric acid, and gamma-amino butyric acid analogs; and iib) a compound that reduces the dendritic cells' ability to activate naïve CD4+ Tcells, such as a cyclooxygenase inhibitor, a CTLA-4 compound or a TNF alpha inhibitor. The invention also relates to pharmaceutical kits and to medical use of beta cell autoantigens.

公开(公告)号：US20240299492A1

公开(公告)日：2024-09-12

申请号：US18279451

申请日：2022-03-04

申请人： Shattuck Labs, Inc.

发明人： Taylor SCHREIBER ,  Suresh DE SILVA ,  George FROMM

IPC分类号： A61K38/17 ,  A61K31/282 ,  A61K31/337 ,  A61K31/439 ,  A61K31/454 ,  A61K31/4745 ,  A61K31/513 ,  A61K31/519 ,  A61K31/635 ,  A61K31/69 ,  A61K31/704 ,  A61K31/706 ,  A61K31/7068 ,  A61K33/243 ,  A61K38/19 ,  A61K39/395 ,  A61K45/06 ,  A61P35/00

CPC分类号： A61K38/1774 ,  A61K31/282 ,  A61K31/337 ,  A61K31/439 ,  A61K31/454 ,  A61K31/4745 ,  A61K31/513 ,  A61K31/519 ,  A61K31/635 ,  A61K31/69 ,  A61K31/704 ,  A61K31/706 ,  A61K31/7068 ,  A61K33/243 ,  A61K38/191 ,  A61K39/3955 ,  A61K45/06 ,  A61P35/00

摘要： The present disclosure relates to, inter alia, combinations of compositions which include chimeric proteins that find use in methods for treating disease, such as immunotherapies for cancer.

公开(公告)号：US12076307B2

公开(公告)日：2024-09-03

申请号：US16888716

申请日：2020-05-30

申请人： Enzychem Lifesciences Corporation

发明人： Ki Young Sohn ,  Sun Young Yoon

IPC分类号： A61K31/231 ,  A61K38/19 ,  A61K45/06 ,  A61P39/00 ,  A61P43/00

CPC分类号： A61K31/231 ,  A61K38/193 ,  A61K45/06 ,  A61P39/00 ,  A61P43/00

摘要： In one aspect, use of 1-palmitoyl-2-linoleoyl-3-acetylglycerol (PLAG) for treating or preventing acute radiation syndrome is provided.

公开(公告)号：US20240285701A1

公开(公告)日：2024-08-29

申请号：US18635627

申请日：2024-04-15

申请人： THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK

发明人： Virginia Cornish ,  Amirhossein JAFARIYAN

IPC分类号： A61K36/064 ,  A61K9/00 ,  A61K9/06 ,  A61K38/18 ,  A61K38/19 ,  A61K38/20 ,  A61K38/39 ,  A61K38/55 ,  A61K45/06 ,  A61K47/36 ,  A61P17/00 ,  A61P17/02 ,  A61P17/06

CPC分类号： A61K36/064 ,  A61K9/0014 ,  A61K9/06 ,  A61K38/1808 ,  A61K38/1841 ,  A61K38/1866 ,  A61K38/195 ,  A61K38/2026 ,  A61K38/39 ,  A61K38/55 ,  A61K45/06 ,  A61K47/36 ,  A61P17/00 ,  A61P17/02 ,  A61P17/06

摘要： The disclosed subject matter provides for genetically modified cells, e.g., fungal cells, that autonomously generates and/or secretes one or more skin therapeutics, and methods of use thereof. In certain embodiments, the present disclosure provides genetically-engineered fungal cells that generate and secrete growth factors, protease inhibitors, cytokines and/or chemokines and methods of use thereof, e.g., for treating skin conditions.

公开(公告)号：US12070473B2

公开(公告)日：2024-08-27

申请号：US16759293

申请日：2018-04-24

申请人： LIFT BIOSCIENCES LTD

发明人： Alex Blyth ,  Nico Bruyniks

IPC分类号： A61K35/15 ,  A61K31/198 ,  A61K31/202 ,  A61K31/375 ,  A61K31/59 ,  A61K35/28 ,  A61K38/19 ,  A61K38/20 ,  A61K38/27 ,  A61P35/00 ,  C12N5/0787 ,  C12N5/0789 ,  G01N33/574 ,  A61K48/00

CPC分类号： A61K35/15 ,  A61K31/198 ,  A61K31/202 ,  A61K31/375 ,  A61K31/59 ,  A61K35/28 ,  A61K38/193 ,  A61K38/20 ,  A61K38/27 ,  A61P35/00 ,  C12N5/0642 ,  C12N5/0647 ,  G01N33/57438 ,  C12N2500/32 ,  C12N2500/38 ,  C12N2501/02 ,  C12N2501/145 ,  C12N2501/22 ,  C12N2501/2303 ,  C12N2501/2304 ,  C12N2501/2306 ,  C12N2501/2308 ,  C12N2501/2318 ,  C12N2501/25 ,  C12N2501/26 ,  C12N2501/305 ,  C12N2501/825 ,  C12N2506/11 ,  C12N2506/45

摘要： The present invention relates to an in vitro culture of haematopoietic cells, wherein the haematopoietic cells differentiate to form granulocytes characterised by the ability to kill cancer cells. The invention also relates to the granulocytes, methods for identifying the haematopoietic cells and granulocytes, compositions and kits comprising the same, as well as uses of the same for treating cancer.